Pfizer ($PFE) may finally be turning the corner on its post-pandemic revenue challenges. The company recently reported breakthrough survival data ...

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

Oncology sales comprise more than 25% of Pfizer’s total revenues. Its oncology revenues grew 9% in the first half of 2025, ...

PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer ca ...

Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

AbbVie unveiled a $195 million investment to expand active pharmaceutical ingredient manufacturing in the U.S. Bloomberg reported that BlinkRx, a company that has Donald Trump Jr. on its board, just ...

Exelixis ’ EXEL year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the ...

Exelixis (EXEL) is developing zanzalintinib — a next-generation oral investigational tyrosine kinase inhibitor (TKI) — which ...